title: Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.
abstract: Rhesus macaques chronically infected with highly pathogenic simian immunodeficiency virus (SIV) SIVmac251 were treated with antiretroviral drugs and vaccinated with combinations of DNA vectors expressing SIV antigens. Vaccination during therapy increased cellular immune responses. After the animals were released from therapy, the virus levels of 12 immunized animals were significantly lower (P = 0.001) compared to those of 11 animals treated with only antiretroviral drugs. Vaccinated animals showed a persistent increase in immune responses, thus indicating both a virological and an immunological benefit following DNA therapeutic vaccination. Several animals show a long-lasting decrease in viremia, suggesting that therapeutic vaccination may provide an additional benefit to antiretroviral therapy.
authors.affiliation: Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, 1050 Boyles Street, Building 535, Room 210, Frederick, MD 21702-1201, USA.
authors.forename: Agneta S
authors.initials: AS
authors.lastname: von Gegerfelt
authors.forename: Margherita
authors.initials: M
authors.lastname: Rosati
authors.forename: Candido
authors.initials: C
authors.lastname: Alicea
authors.forename: Antonio
authors.initials: A
authors.lastname: Valentin
authors.forename: Patricia
authors.initials: P
authors.lastname: Roth
authors.forename: Jenifer
authors.initials: J
authors.lastname: Bear
authors.forename: Genoveffa
authors.initials: G
authors.lastname: Franchini
authors.forename: Paul S
authors.initials: PS
authors.lastname: Albert
authors.forename: Norbert
authors.initials: N
authors.lastname: Bischofberger
authors.forename: Jean D
authors.initials: JD
authors.lastname: Boyer
authors.forename: David B
authors.initials: DB
authors.lastname: Weiner
authors.forename: Phillip
authors.initials: P
authors.lastname: Markham
authors.forename: Zimra R
authors.initials: ZR
authors.lastname: Israel
authors.forename: John H
authors.initials: JH
authors.lastname: Eldridge
authors.forename: George N
authors.initials: GN
authors.lastname: Pavlakis
authors.forename: Barbara K
authors.initials: BK
authors.lastname: Felber
mesh_terms: D000818:Animals; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000956:Antigens, Viral / Q000276:immunology; D002908:Chronic Disease; D004353:Drug Evaluation, Preclinical; D007273:Injections, Intramuscular; D008253:Macaca mulatta; D018449:SAIDS Vaccines / Q000008:administration & dosage*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000628:therapy* / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology; D019562:Viral Load / Q000662:veterinary; D014765:Viral Vaccines
chemical_list: D044966:Anti-Retroviral Agents; D000956:Antigens, Viral; D018449:SAIDS Vaccines; D019444:Vaccines, DNA; D014765:Viral Vaccines